Explore more publications!
Today in Medicine
Got News to Share?

Press Releases

Laccura Medical Group, Where Wellness Becomes Beauty
Feb. 19, 2026

Laccura Medical Group, Where Wellness Becomes Beauty

Neutral EIN Presswire
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
Feb. 19, 2026

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Indeterminate GlobeNewswire, Inc.
PMI INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Picard Medical (PMI) Investors of Securities Class Action Deadline on April 13, 2026
Feb. 19, 2026

PMI INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Picard Medical (PMI) Investors of Securities Class Action Deadline on April 13, 2026

Indeterminate GlobeNewswire, Inc.
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Feb. 19, 2026

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Indeterminate GlobeNewswire, Inc.
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Feb. 19, 2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Indeterminate GlobeNewswire, Inc.
Medical Simulation Industry Growth to Hit US$5.6Bn by 2032 – Persistence Market Resaerch
Feb. 17, 2026

Medical Simulation Industry Growth to Hit US$5.6Bn by 2032 – Persistence Market Resaerch

Neutral EIN Presswire
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
Feb. 19, 2026

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia

Indeterminate GlobeNewswire, Inc.
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Feb. 19, 2026

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Indeterminate GlobeNewswire, Inc.
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
Feb. 19, 2026

Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours

Indeterminate GlobeNewswire, Inc.
INO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
Feb. 19, 2026

INO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Indeterminate GlobeNewswire, Inc.
RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Feb. 19, 2026

RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Indeterminate GlobeNewswire, Inc.
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
Feb. 19, 2026

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

Indeterminate GlobeNewswire, Inc.
Zealand Pharma Announces Financial Results for the Full Year 2025
Feb. 19, 2026

Zealand Pharma Announces Financial Results for the Full Year 2025

Indeterminate GlobeNewswire, Inc.
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine
Feb. 19, 2026

BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine

Indeterminate GlobeNewswire, Inc.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
Feb. 19, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Indeterminate GlobeNewswire, Inc.
ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine
Feb. 18, 2026

ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine

Indeterminate GlobeNewswire, Inc.
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Feb. 18, 2026

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Indeterminate GlobeNewswire, Inc.
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Feb. 18, 2026

Eupraxia Pharmaceuticals Announces Proposed Public Offering

Indeterminate GlobeNewswire, Inc.
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Feb. 18, 2026

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East

Indeterminate GlobeNewswire, Inc.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Picard Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PMI
Feb. 18, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Picard Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PMI

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions